Thermo Fisher Scientific CD19 Monoclonal Antibody (LT19), Biotin

Applications

Flow Cytometry (Flow)

• Tested Dilution: 3–5 µg/mL

Immunoprecipitation (IP)

• Tested Dilution: Assay-dependent

Product Specifications

Additional Formats

• Unconjugated
• APC
• FITC
• PE
• PerCP
• Request custom conjugation

Product Specific Information

This antibody reacts with an extracellular epitope of CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.

Target Information

CD19 is a member of the immunoglobulin superfamily and has two Ig-like domains. The CD19 molecule is expressed on 100% of peripheral B cells as defined by expression of kappa or lambda light chains.
CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen.
The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation and is expressed in all B cell precursor leukemias.
CD19 assembles with the antigen receptor of B lymphocytes to decrease the threshold for antigen receptor-dependent stimulation.
Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge.
Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.